tiprankstipranks
Advertisement
Advertisement

ALLO Stock Latest News

Allogene Therapeutics price target lowered to $11 from $12 at H.C. Wainwright
The FlyAllogene Therapeutics price target lowered to $11 from $12 at H.C. Wainwright
1d ago
ALLO
Allogene Therapeutics upgraded to Neutral from Underweight at JPMorgan
PremiumThe Fly
Allogene Therapeutics upgraded to Neutral from Underweight at JPMorgan
1d ago
ALLO
Allogene Therapeutics Prices Large Common Stock Offering
PremiumCompany Announcements
Allogene Therapeutics Prices Large Common Stock Offering
2d ago
8K
ALLO
Allogene Therapeutics price target raised to $10 from $6 at Jefferies
PremiumThe Fly
Allogene Therapeutics price target raised to $10 from $6 at Jefferies
2d ago
ALLO
Unusually active option classes on open April 15th
PremiumThe Fly
Unusually active option classes on open April 15th
2d ago
AEO
ALLO
Allogene Therapeutics 87.5M share Spot Secondary priced at $2.00
PremiumThe FlyAllogene Therapeutics 87.5M share Spot Secondary priced at $2.00
3d ago
ALLO
Allogene Therapeutics price target raised to $3.85 from $1.60 at Bernstein
Premium
The Fly
Allogene Therapeutics price target raised to $3.85 from $1.60 at Bernstein
3d ago
ALLO
Allogene Therapeutics price target raised to $9 from $7 at Baird
Premium
The Fly
Allogene Therapeutics price target raised to $9 from $7 at Baird
3d ago
ALLO
Allogene Therapeutics price target raised to $12 from $8 at H.C. Wainwright
PremiumThe Fly
Allogene Therapeutics price target raised to $12 from $8 at H.C. Wainwright
3d ago
ALLO
Allogene Therapeutics price target raised to $8 from $5 at Citizens
PremiumThe Fly
Allogene Therapeutics price target raised to $8 from $5 at Citizens
3d ago
ALLO
Cellectis highlights Allogene ALPHA3 trial data, potential milestone payments
PremiumThe Fly
Cellectis highlights Allogene ALPHA3 trial data, potential milestone payments
4d ago
ALLO
CLLS
Allogene Therapeutics Launches New Underwritten Common Stock Offering
PremiumCompany Announcements
Allogene Therapeutics Launches New Underwritten Common Stock Offering
4d ago
8K
ALLO
Allogene Therapeutics announces $175M common stock offering
PremiumThe FlyAllogene Therapeutics announces $175M common stock offering
4d ago
ALLO
Midday Fly By: Goldman reports Q1 beat, Baker Hughes to sell Waygate
Premium
The Fly
Midday Fly By: Goldman reports Q1 beat, Baker Hughes to sell Waygate
4d ago
GS
BBY
Morning Movers: Leggett & Platt gains, Somnigroup lower after $2.5B deal
Premium
The Fly
Morning Movers: Leggett & Platt gains, Somnigroup lower after $2.5B deal
4d ago
GS
BBY
Allogene Therapeutics: Strong ALPHA3 Futility Data and Favorable Safety Profile Support Buy Rating and Blockbuster Potential for Cema-cel in LBCL
PremiumRatings
Allogene Therapeutics: Strong ALPHA3 Futility Data and Favorable Safety Profile Support Buy Rating and Blockbuster Potential for Cema-cel in LBCL
4d ago
ALLO
Allogene Highlights Positive Interim ALPHA3 CAR T Data
PremiumCompany Announcements
Allogene Highlights Positive Interim ALPHA3 CAR T Data
4d ago
8K
ALLO
Natera highlights Allogene Therapeutics’ analysis from ALPHA3 trial
PremiumThe Fly
Natera highlights Allogene Therapeutics’ analysis from ALPHA3 trial
4d ago
ALLO
NTRA
Allogene Therapeutics data from ALPHA3 trial a ‘home run,’ says TD Cowen
PremiumThe Fly
Allogene Therapeutics data from ALPHA3 trial a ‘home run,’ says TD Cowen
4d ago
ALLO
Allogene Therapeutics reports data from ALPHA3 trial
PremiumThe FlyAllogene Therapeutics reports data from ALPHA3 trial
4d ago
ALLO
Allogene Therapeutics Faces Trial Setback as ALLO-647 Halt Raises Lymphodepletion and Regulatory Timeline Risks
Premium
Company Announcements
Allogene Therapeutics Faces Trial Setback as ALLO-647 Halt Raises Lymphodepletion and Regulatory Timeline Risks
1M ago
ALLO
Allogene Therapeutics Banks on 2026 Trial Catalysts
Premium
Company Announcements
Allogene Therapeutics Banks on 2026 Trial Catalysts
1M ago
ALLO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >